Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies-Reference-Cited by-同舟云学术

Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies

Published:2010-06 Issue:5 Volume:33 Page:500-509
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Liu Rong,Jiang Wenguo,Yang Ming,Guo Hongxing,Zhang Yanjun,Wang Jinhong,Zhu Huifang,Shi Ruizan,Fan Dongmei,Yang Chunzheng,Zhu Zhenping,Xie Yong,Xiong Dongsheng

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference41 articles.

1. Minimal residual disease: detection, clinical relevance, and treatment strategies;Dwenger;J Hematother,1996

2. Characterization of a human B lymphocyte specific antigen;Stashenko;J Immunol,1980

3. Signal amplification in molecular imaging by pretargeting a multivalent bispecific diabodies;Sharkey;Nat Med,2005

4. Immune suppression in the tumor microenvironment;Gajewski;J Immunother,2006

5. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression;Ahmad;Cancer Immunol Immunother,2004

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry;RSC Chemical Biology;2022

2. Biology and Clinical Evaluation of T/NK Cell Engagers;Cancer Drug Discovery and Development;2022

3. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies;Cancer Immunotherapies;2022

4. The landscape of bispecific T cell engager in cancer treatment;Biomarker Research;2021-05-26

5. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors;Cancers;2021-01-14